138 related articles for article (PubMed ID: 36271947)
1. Starting dose selection of palbociclib in Chinese patients with breast cancer based on population kinetic-pharmacodynamic model of neutropenia.
Jian W; Xue J; Yao Q; Chen R; Yao Y; Wang M; Zhou T
Cancer Chemother Pharmacol; 2022 Dec; 90(6):489-497. PubMed ID: 36271947
[TBL] [Abstract][Full Text] [Related]
2. Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation Approach.
Sun W; O'Dwyer PJ; Finn RS; Ruiz-Garcia A; Shapiro GI; Schwartz GK; DeMichele A; Wang D
J Clin Pharmacol; 2017 Sep; 57(9):1159-1173. PubMed ID: 28419480
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic/Pharmacodynamic Model of Neutropenia in Real-Life Palbociclib-Treated Patients.
Marouille AL; Petit E; Kaderbhaï C; Desmoulins I; Hennequin A; Mayeur D; Fumet JD; Ladoire S; Tharin Z; Ayati S; Ilie S; Royer B; Schmitt A
Pharmaceutics; 2021 Oct; 13(10):. PubMed ID: 34684001
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the Association of Polymorphisms With Palbociclib-Induced Neutropenia: Pharmacogenetic Analysis of PALOMA-2/-3.
Iwata H; Umeyama Y; Liu Y; Zhang Z; Schnell P; Mori Y; Fletcher O; Marshall JC; Johnson JG; Wood LS; Toi M; Finn RS; Turner NC; Bartlett CH; Cristofanilli M
Oncologist; 2021 Jul; 26(7):e1143-e1155. PubMed ID: 33955129
[TBL] [Abstract][Full Text] [Related]
5. Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2- Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial.
Diéras V; Harbeck N; Joy AA; Gelmon K; Ettl J; Verma S; Lu DR; Gauthier E; Schnell P; Mori A; Rugo HS; Finn RS
Oncologist; 2019 Dec; 24(12):1514-1525. PubMed ID: 31217344
[TBL] [Abstract][Full Text] [Related]
6. Population Pharmacokinetics of Palbociclib and Its Correlation with Clinical Efficacy and Safety in Patients with Advanced Breast Cancer.
Courlet P; Cardoso E; Bandiera C; Stravodimou A; Zurcher JP; Chtioui H; Locatelli I; Decosterd LA; Darnaud L; Blanchet B; Alexandre J; Wagner AD; Zaman K; Schneider MP; Guidi M; Csajka C
Pharmaceutics; 2022 Jun; 14(7):. PubMed ID: 35890213
[TBL] [Abstract][Full Text] [Related]
7. Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia.
Hing J; Perez-Ruixo JJ; Stuyckens K; Soto-Matos A; Lopez-Lazaro L; Zannikos P
Clin Pharmacol Ther; 2008 Jan; 83(1):130-43. PubMed ID: 17597713
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamic Modeling of CDK4/6 Inhibition-Related Biomarkers and the Characterization of the Relationship Between Biomarker Response and Progression-Free Survival in Patients With Advanced Breast Cancer.
Yu Y; Sun W; Liu Y; Wang D
J Clin Pharmacol; 2022 Mar; 62(3):376-384. PubMed ID: 34554584
[TBL] [Abstract][Full Text] [Related]
9. Real-world evidence analysis of palbociclib prescribing patterns for patients with advanced/metastatic breast cancer treated in community oncology practice in the USA one year post approval.
Kish JK; Ward MA; Garofalo D; Ahmed HV; McRoy L; Laney J; Zanotti G; Braverman J; Yu H; Feinberg BA
Breast Cancer Res; 2018 May; 20(1):37. PubMed ID: 29720233
[TBL] [Abstract][Full Text] [Related]
10. Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3).
Verma S; Bartlett CH; Schnell P; DeMichele AM; Loi S; Ro J; Colleoni M; Iwata H; Harbeck N; Cristofanilli M; Zhang K; Thiele A; Turner NC; Rugo HS
Oncologist; 2016 Oct; 21(10):1165-1175. PubMed ID: 27368881
[TBL] [Abstract][Full Text] [Related]
11. Real-world benefit of combination palbociclib and endocrine therapy for metastatic breast cancer and correlation with neutropenia.
Sun J; Zhong X; Ma J; Sun W; Han HS; Soliman HH; Loftus LS; Costa RLB; Armaghani AJ; Soyano-Muller AE; Czerniecki BJ; Lee MC; Kiluk JV; Khakpour N; Hoover SJ; Laronga C; Khong HT
Cancer Med; 2021 Nov; 10(21):7665-7672. PubMed ID: 34590788
[TBL] [Abstract][Full Text] [Related]
12. Risk factors associated with palbociclib-induced neutropenia in patients with metastatic breast cancer.
Lavery L; DiSogra K; Lea J; Trufan SJ; Symanowski JT; Roberts A; Moore DC; Heeke A; Pal S
Support Care Cancer; 2022 Dec; 30(12):9803-9809. PubMed ID: 36260177
[TBL] [Abstract][Full Text] [Related]
13. Progression-Free Survival for Real-World Use of Palbociclib in Hormone Receptor-Positive Metastatic Breast Cancer.
Wilkie J; Schickli MA; Berger MJ; Lustberg M; Reinbolt R; Noonan A; Ramaswamy B; Sardesai S; VanDeusen J; Wesolowski R; Williams N; Stover DG; Li J; Vargo CA
Clin Breast Cancer; 2020 Feb; 20(1):33-40. PubMed ID: 31451366
[TBL] [Abstract][Full Text] [Related]
14. Ribociclib Population Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Analysis of Neutrophils in Cancer Patients.
Lu Y; Yang S; Ho YY; Ji Y
J Clin Pharmacol; 2021 Aug; 61(8):1054-1068. PubMed ID: 33713359
[TBL] [Abstract][Full Text] [Related]
15. Real-World Predictors of Severe Neutropenia Associated with Palbociclib and Endocrine Therapy for Metastatic Breast Cancer in Japanese Patients.
Takada S; Maeda H; Umehara K; Kuwahara S; Yamamoto M; Tomioka N; Watanabe K; Mino K
Biol Pharm Bull; 2023; 46(8):1105-1111. PubMed ID: 37532561
[TBL] [Abstract][Full Text] [Related]
16. Racial disparities in neutrophil counts among patients with metastatic breast cancer during treatment with CDK4/6 inhibitors.
Schreier A; Munoz-Arcos L; Alvarez A; Sparano JA; Anampa JD
Breast Cancer Res Treat; 2022 Jul; 194(2):337-351. PubMed ID: 35633421
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetic-pharmacodynamic modeling and model-based prediction of docetaxel-induced neutropenia in Japanese patients with non-small cell lung cancer.
Fukae M; Shiraishi Y; Hirota T; Sasaki Y; Yamahashi M; Takayama K; Nakanishi Y; Ieiri I
Cancer Chemother Pharmacol; 2016 Nov; 78(5):1013-1023. PubMed ID: 27709284
[TBL] [Abstract][Full Text] [Related]
18. Neutropenia management with palbociclib in Japanese patients with advanced breast cancer.
Masuda N; Mukai H; Inoue K; Rai Y; Ohno S; Mori Y; Hashigaki S; Muramatsu Y; Umeyama Y; Iwata H; Toi M
Breast Cancer; 2019 Sep; 26(5):637-650. PubMed ID: 31127500
[TBL] [Abstract][Full Text] [Related]
19. Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer.
Ham A; Kim MH; Kim GM; Kim JH; Kim JY; Park HS; Park S; Cho YU; Park BW; Kim SI; Sohn J
Breast Cancer Res Treat; 2020 Aug; 183(1):107-116. PubMed ID: 32577940
[TBL] [Abstract][Full Text] [Related]
20. PALINA: A phase II safety study of palbociclib in combination with letrozole or fulvestrant in African American women with hormone receptor positive HER2 negative advanced breast cancer.
Lynce F; Saleh M; Shajahan-Haq A; Gallagher C; Dilawari A; Hahn O; Abu-Khalaf M; Cai L; Pohlmann P; Mohebtash M; Kamugisha L; Isaacs C
Contemp Clin Trials Commun; 2018 Jun; 10():190-192. PubMed ID: 30009277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
